Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials

Table 1 Characteristic of randomized controlled trials included

Reference	phase	Country	Asthma severity	Patients(n) dupilumab/placebo	Treatment duration	Follow up	Dosage	Outcomes
Wenzel 2013 [27]	2A	The US	Moderate-to-severe; blood eosinophil count of at least 300 cells/μl	52/52	12 weeks	8 weeks	300 mg q1w	FEV₁; PEF; ACQ5 score; FE_NO; Asthma exacerbations; Morning and evening asthma score
Wenzel 2016 [15]	2b	Multinational	Uncontrolled moderate-to-severe asthma	611/158	24 weeks	12 weeks	200 mg q4w 300 mg q4w 200 mg q2w 300 mg q2w	FEV₁; ACQ5 score; FE_NO; AQLQ; Severe asthma exacerbations; Morning and evening asthma score
Castro 2018 [26]	3	Multinational	Uncontrolled moderate-to-severe asthma	Group 1: 631/313 Group 2: 632/321	52 weeks	12 weeks	200 mg q2w 300 mg q2w	FEV₁; PEF; ACQ5 score; FE_NO; AQLQ; Severe asthma exacerba-tions; Morning and evening asthma score
Rabe 2018 [25]	3	Multinational	Oral glucocorticoid–dependent severe asthma	103/107	24 weeks	NM	300 mg q2w	FEV₁; FE_NO; Severe asthma exacerbations Reduction in the oral glucocorticoid dose
Weinstein 2018 [24]	2b	Multinational	Uncontrolled persistent asthma	Group 1: 92/56 Group 2: 157/84	24 weeks	NM	200 mg q2w 300 mg q2w	FEV₁; Severe asthma exacerbations

Abbreviations: FEV₁ forced expiratory volume in 1 s, PEF peak expiratory flow, ACQ-5 5-item Asthma Control Questionnaire, FE_NO fractional exhaled nitric oxide, AQLQ the Asthma Quality of Life Questionnaire, NM not mentioned, q1w once weekly, q2w every 2 weeks, q4w every 4 weeks

ISSN: 1465-993X